Pennsylvania-based Recro Pharma has picked up a new plant and jumped into the contract manufacturing business, while Irish drugmaker Alkermes is now one plant shorter and out of the CMO biz.
Quest Diagnostics is partnering with contract research organization Quintiles to create a joint venture to provide a range of clinical trial services to biopharmas including laboratory testing and patient recruitment and retention as well as development and commercialization of companion diagnostics.
Ophthalmic and surgical sutures for holding tissue together after medical procedures will no longer be made in Exeter Township, PA, thanks to the upcoming closure of the Surgical Specialties' manufacturing plant in the Philadelphia suburb. It will come at a cost of 254 jobs.
Norwegian drugmaker Weifa figures its consumer health biz and its contract active pharmaceutical ingredient operations both have a better shot at growth if they go their separate ways. To make that happen, Weifa plans on spinning the API business off into a contract manufacturing operation, with its first contract to make the APIs for Weifa.
In an effort to expand into life sciences, Tokyo-based JSR, a materials producer with 5,500 employees, has announced its intention to acquire Durham, NC-based contract manufacturer KBI Biopharma.
Outsourced product design specialist TE Connectivity will increase its focus on medical devices with its $190 million purchase of catheter player AdvancedCath.
The head of the U.K.'s Trade & Investment Ministry has begun a three-day visit to India to focus on biotech and health issues, beginning with the Bangalore India Bio, the nation's major biotech conference.
In a no-holds-barred action, the European Medicines Agency has accused India-based CRO GVK Biosciences of systematically faking clinical trials for about 700 generic drugs marketed throughout the world. The products of dozens of generic makers are among the drugs involved, including popular antidepressants.
China biotech Innovent's recent success in raising $100 million in venture capital to help it build a pipeline of biosimilars could be a signal of how the industry may be set to explode in a country about to invest $6.45 billion in startups.
India's Piramal Enterprises said it was on the cusp of buying a CDMO founded at the University of Kentucky. That comes weeks after Japan's Fujifilm Diosynth Biotechnologies bought half of a vaccine manufacturing specialist from the Texas A&M University System.